Crispr Therapeutics’ (CRSP) “Buy” Rating Reiterated at Chardan Capital

Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research report issued on Tuesday, AnalystRatings.com reports. They currently have a $72.50 price target on the stock. Chardan Capital’s price target indicates a potential upside of 90.99% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Barclays increased their price target on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Jefferies Financial Group started coverage on shares of Crispr Therapeutics in a research note on Thursday, August 1st. They set a “buy” rating and a $64.00 price target on the stock. BTIG Research increased their price target on shares of Crispr Therapeutics from $51.00 to $59.00 and gave the company a “positive” rating in a research note on Tuesday, July 30th. Canaccord Genuity started coverage on shares of Crispr Therapeutics in a research note on Friday, July 26th. They set a “buy” rating and a $72.00 price target on the stock. Finally, Roth Capital increased their price target on shares of Crispr Therapeutics from $50.00 to $65.00 in a research note on Tuesday, July 30th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $57.25.

Crispr Therapeutics stock traded up $1.28 during trading hours on Tuesday, hitting $37.96. 358,628 shares of the stock were exchanged, compared to its average volume of 609,785. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.96 and a current ratio of 13.96. The stock has a market capitalization of $2.02 billion, a P/E ratio of -11.03 and a beta of 3.11. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $53.90. The business’s 50-day moving average is $43.76 and its two-hundred day moving average is $43.30.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, July 29th. The company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.84). The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $47.57 million. Crispr Therapeutics had a negative return on equity of 51.49% and a negative net margin of 15,136.56%. Crispr Therapeutics’s quarterly revenue was down 70.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.82) earnings per share. On average, equities analysts predict that Crispr Therapeutics will post -3.85 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Benjamin Edwards Inc. lifted its holdings in Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares during the period. US Bancorp DE lifted its holdings in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after buying an additional 526 shares during the period. BSW Wealth Partners acquired a new position in Crispr Therapeutics in the second quarter valued at approximately $39,000. BNP Paribas Arbitrage SA acquired a new position in Crispr Therapeutics in the second quarter valued at approximately $41,000. Finally, Griffin Asset Management Inc. acquired a new position in Crispr Therapeutics in the second quarter valued at approximately $64,000. 50.23% of the stock is currently owned by institutional investors and hedge funds.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: How to track put option volume

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.